• CE-IVD certification of rapid test successfully completed 
  • Mini-laboratory delivers results in about 40 minutes at the point of care 
  • Klinikum Stuttgart uses Spindiag’s Rhonda from day one 
  • Minister of Economic Affairs, Dr. Nicole Hoffmeister-Kraut, to visit COVID-19 care center at Klinikum Stuttgart on November 16, 2020 

Freiburg/Breisgau, Germany, November 16, 2020 – Spindiag GmbH, a fast-growing medical technology startup that developed a point-of-care testing system to detect bacterial and viral pathogens, announced today that it has successfully completed the market entry assessment of its PCR rapid SARS-CoV-2 test. Spindiag’s Rhonda is now rolled out in phases in Germany, the EU, and other countries that accept the CE mark for in vitro diagnostics (CE-IVD). One of the first of these innovative testing devices will be installed at Klinikum Stuttgart, which belongs to the largest and highest-performing hospitals in Germany. As dedicated COVID-19 care center of the metropolitan region, the Klinikum Stuttgart, where more than 100,000 tests on SARS-CoV-2 have already been conducted, plays an important role in managing the pandemic through diagnostics and patient care.

The State Ministry of Economic Affairs, Labor and Housing provided EUR 6 million in funding at the beginning of the pandemic for the development of Rhonda. Minister of Economic Affairs, Dr. Nicole Hoffmeister-Kraut will be visiting the regional COVID-19 care center at the hospital at 1:30 p.m. (CET) to watch the PCR rapid coronavirus test funded by the ministry being used for the first time